Sigachi Industries Limited has secured a crucial regulatory milestone with the approval of Terms of Reference (ToR) from the State Environment Impact Assessment Authority (SEIAA) of Andhra Pradesh for its upcoming pharmaceutical manufacturing facility. The prominent manufacturer of pharmaceutical excipients and active ingredients plans to develop a comprehensive Bulk Drugs, Drug Intermediates, and Specialty Chemicals manufacturing facility in Orvakal, Kurnool District.
Strategic Facility Development
The ambitious project will span 25.09 acres at Plot No. A-10, Guttapadu-Orvakal Node. The facility has been classified under Category B1, aligning with Schedule 5(f) of the Environmental Impact Assessment (EIA) Notification, 2006, which specifically pertains to the Synthetic Organic Chemicals sector.
With the ToR approval now secured, Sigachi has established a clear timeline for the next phases of development. The Environmental Clearance (EC) process is scheduled to commence on July 15, 2025, followed by the initiation of project development activities beginning August 1, 2025.
Manufacturing Capabilities and Market Impact
The new facility is designed to serve multiple strategic objectives for Sigachi Industries. The project will significantly enhance the company's Active Pharmaceutical Ingredients (APIs) manufacturing capacity, enabling expanded presence in global markets. Additionally, the facility will support the growth of Sigachi's product pipeline for both regulated and semi-regulated markets worldwide.
The strategic location in Orvakal has been specifically chosen to maximize export capabilities, positioning the company to better serve international customers and regulatory jurisdictions.
Leadership Vision and Strategic Positioning
Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, emphasized the significance of this development: "This is a significant milestone in our journey to become a vertically integrated pharmaceutical manufacturing company. The Orvakal project will anchor our next phase of growth in APIs and specialty chemicals, helping us create scalable, sustainable, and compliant operations for global markets."
Sinha further outlined the strategic rationale behind the expansion: "At Sigachi, we are strategically positioning ourselves to cater to increasing global demand by building capacity closer to key markets and regulatory jurisdictions. The new facility will not only strengthen our product supply chain but also enable faster commercialization, seamless tech transfers, and enhanced responsiveness to evolving customer requirements."
Alignment with National Initiatives
The project demonstrates alignment with India's "Make in India" initiative, featuring world-class infrastructure and a commitment to sustainable manufacturing practices. This positioning supports both national pharmaceutical manufacturing goals and the company's global competitiveness strategy.
